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Summary
 
Development of T helper cell (Th)1 or Th2 cytokine responses is essential for effector and reg-
ulatory functions of T helper cells. We have compared cytokine profiles of myelin basic protein
(MBP) Ac1-16 peptide-specific T helper cells from inbred mouse strains expressing identical 
 
k
 
haplotype-derived MHC class II molecules B10.A and B10.BR. B10.BR T cell lines (TCL)
produced Th1 cytokines (including high levels of TNF-
 
a
 
) and induced experimental autoim-
mune encephalomyelitis after adoptive transfer. In contrast, B10.A TCL produced Th2 cyto-
kines (including low levels of TNF-
 
a
 
) and were poorly encephalitogenic. The contributions of
the genetic origin of the T cells and the APC were explored. Serial restimulations of the
B10.BR TCL with B10.A or (B10.A 
 
3
 
 B10.BR) F1 splenic antigen presenting cells (APC)
during the establishment of TCL markedly reduced both Th1 cytokine production and en-
cephalitogenicity. In addition, a single restimulation with B10.A splenic APC reduced IFN-
 
g
 
and TNF-
 
a
 
 production by established Th1 MBP-specific A
 
k
 
-restricted B10.BR TCL and by a
Th1 KLH-specific, E
 
k
 
-restricted B10.BR T cell clone. These studies suggest that B10.A and
B10.BR APC differ in their ability to stimulate IFN-
 
g
 
 and TNF-
 
a
 
 production by mature Th1
cells and also influence their Th1/Th2 commitment in vivo. The nature of the downregulatory
activity of B10.A APC on IFN-
 
g
 
 and TNF-
 
a
 
 production was explored. 2-hour supernatants
from antigen-activated B10.A APC/TCL cultures or from B10.A APC activated by LPS had
the same inhibitory effects on IFN-
 
g
 
 and TNF-
 
a
 
 production by B10.BR TCL. The downreg-
ulatory effects of B10.A APC are independent of TNF-
 
a
 
, IL-4, IL-10, IL-12p40, IFN-
 
g
 
, IL-13,
TGF-
 
b
 
, and PGE2. Thus, genetic difference(s) between B10.A and B10.BR APC appear(s) to
control the production or activity of a novel soluble cytokine regulatory factor that influences
Th1/Th2 commitment and controls production of IFN-
 
g
 
 and TNF-
 
a
 
 by mature Th1 cells.
 
M
 
ost mature CD4
 
1
 
 T helper cells express one of two
cytokine profiles: Th1 or Th2. Th1s secrete IL-2,
IL-3, IFN-
 
g
 
, TNF-
 
b
 
, GM-CSF, and high levels of TNF-
 
a
 
.
Th2s express IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13,
GM-CSF, and low levels of TNF-
 
a
 
 (1–3). These cytokine
profiles determine T cell regulatory and effector functions
in immune responses (4–8). The Th1 subset promotes de-
layed-type hypersensitivity, cell-mediated immunity, and
immunoglobulin class switching to IgG2a. The Th2 subset
induces humoral immunity by activating B cells, promot-
ing antibody production, and inducing class switching to
IgG1 and IgE. Skewing the T cell responses toward Th1 is
thought to result in susceptibility to autoimmune and in-
flammatory diseases; skewing toward Th2 cytokines pro-
motes allergic reactions.
Several factors have been shown to influence commit-
ment to Th1 or Th2 profiles. The best characterized regu-
lators are cytokines. IL-12 and IFN-
 
g
 
 are positive Th1 and
negative Th2 regulators (9–15). IL-12 promotes IFN-
 
g
 
production, and IFN-
 
g
 
 provides positive feedback for IL-12.
IL-4 and IL-10 appear to be required for the establishment
of the Th2 cytokine profile and to downregulate Th1 cy-
tokine production; the effects of IL-4 have been demon-
strated to be dominant over those of IL-12 (16–21). IL-13
was shown to inhibit expression of inflammatory cytokines,
including IL-12 and TNF-
 
a
 
, by LPS-induced monocytes
in a way similar to IL-4 (22–24). The IL-12 p40 homo-
dimer binds to the IL-12 receptor and antagonizes IL-12
biological activity (25, 26); thus, it blocks the pro-Th1 effects
of IL-12. TGF-
 
b
 
 is also implicated in Th1/Th2 regulation,
although its role remains controversial. It was implicated in
the suppression of the Th1 response in autoimmune en-
cephalomyelitis (27); however, TGF-
 
b
 
 was also shown to
enhance the Th1 phenotype (28, 29). Recently, opposing
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effects of TGF-
 
b
 
 on Th1 development were shown to cor-
relate with the amounts of IL-2 produced in the presence
of this molecule (30).
Signals through the TCR and co-stimulatory molecules
have also been shown to influence Th commitment. Th1
development was found to be associated with high affinity
binding of a peptide antigen to MHC class II and strong
signaling through the TCR, whereas lower affinity anti-
gen–MHC II interactions and weaker signaling through
TCR were reported to result in Th2 cytokine responses
(31, 32). Several cell surface molecules expressed by APC
and T cells have been suggested to influence commitment
to Th1 or Th2 response, including CD40-CD40 ligand in-
teractions and B7.1 versus B7.2 signaling (33–40). At the
cellular level, at least in some cases, macrophages and den-
dritic cells appear to promote the Th1 response, whereas B
cells upregulate Th2 cytokines (41–43). However, neither
the B7.1/B7.2 effects, nor the effects of different APC
types in supporting Th1 or Th2, are absolute (3).
The mechanisms regulating development and expression
of Th1 and Th2 cytokine phenotypes have not been fully
described. The identification and characterization of genes
influencing Th1/Th2 commitment are likely to provide
key insights into this process. Studies of 
 
Leishmania
 
 infec-
tions and autoimmunity implicate both MHC and non-
MHC genes in the development of specific cytokine re-
sponses in humans and animals (8, 44–48). C57BL/6,
B10.D2, and CH3/HeN mouse strains, among many oth-
ers, are predisposed to Th1 responses, and the BALB/c
background is known to promote the Th2 cytokine profile
in response to a wide variety of parasites and antigens (47,
49–50). Recently, the predisposition of BALB cells to de-
velop the Th2 profile was associated with the failure to re-
spond to IL-12 (51).
This study began with a comparison of encephalitogen-
icity of myelin basic protein (MBP)
 
1
 
–specific T cell lines
(TCL) from two A
 
k
 
-expressing 
 
H-2
 
 congenic mouse strains,
B10.A and B10.BR, previously described as being resistant
to 
 
Leishmania tropica major
 
 (44), i.e., predisposed to the Th1
cytokine profile. Experimental autoimmune encephalomy-
elitis (EAE) is a neurological disease considered to be an
animal model of multiple sclerosis. It can be induced in
two ways: by direct immunization with MBP, proteolipid
protein, or their peptides in adjuvant combined with intra-
venous injections of Pertussis toxin, or by adoptive transfer
using activated T cells specific for these antigens. Effector
CD4
 
1
 
 T cells are thought to induce a DTH-like reaction in
the central nervous system which results in demyelination
and paralysis (8). Th1 cytokine responses, including high TNF
expression and high levels of VLA-4, have been shown to
be necessary for development of EAE (52–56).
Adoptive transfer experiments show that MBP-specific
TCL from B10.BR mice induce severe EAE, whereas TCL
from B10.A and (B10.BR 
 
3
 
 B10.A) F1 mice are weakly
encephalitogenic. Our data further suggest that the differ-
ences in encephalitogenicity correlate with Th1/Th2 cy-
tokine profiles. Genetic difference(s) between these strains
appears to control a novel secreted factor regulating cyto-
kine responses of T cells specific for mouse MBP (mMBP)
and probably for other antigens as well.
 
Materials and Methods
 
Animals.
 
B10.A, B10.BR, and B10.PL mice, 6–9 wk old,
were obtained from Jackson Laboratory (Bar Harbor, ME);
(B10.A 
 
3
 
 B10.BR) F1, F2, and (B10.BR 
 
3
 
 F1) backcross mice
were bred in our facility.
 
Antibodies.
 
Anti–IL-4 mAb 11B11 was provided by J. O’hara
and W.E. Paul (National Institutes of Health). Anti–IFN-
 
g
 
 mAb
XMG1.2 was provided by T. Mosmann (University of Alberta,
Edmonton, Canada). Anti–IFN-
 
g
 
 mAb HB170 was obtained from
American Type Culture Collection (Rockville, MD). Anti–IL-4
mAb BVD4 and BVD6, and anti–IL-10 mAb 2A5 and Sxc.1
were provided by M. Howard (DNAX Research Institute, Palo
Alto, CA). Anti–IL-12 p40 mAb C17.8 and C15.6 were provided
by G. Trinchieri (Wistar Institute of Anatomy and Biology, Phila-
delphia, PA). Anti–TNF-
 
a
 
 mAb was provided by Robert Schreiber
(Washington School of Medicine, St. Louis, MO). Anti–IL-13
and anti–TGF-
 
b
 
 pan-neutralizing antibodies were purchased
from R&D Sys., Inc. (Minneapolis, MN).
 
Peptides.
 
mMBP Ac1-16 (Ac-ASQKRPSQRSKYLATA) was
purchased from the Protein and Nucleic Acids Facility (Stanford
University, Stanford, CA).
 
TCL.
 
Mice were immunized in the base of the tail with 100
 
m
 
M mMBP Ac1-16 in CFA H37 Ra (Difco, Detroit, MI). 8 d
later superficial inguinal and sacral lymph nodes were removed,
and lymph node cells were stimulated with 30 
 
m
 
M mMBP Ac1-
16 in RPMI 1640 (GIBCO BRL, Gaithersburg, MD) with 2%
syngeneic mouse serum. Every 10–14 d thereafter, 0.5–1 
 
3
 
 10
 
6
 
 T
cells were restimulated with 30 
 
m
 
M mMBP Ac1-16 and 5 
 
3
 
 10
 
6
 
irradiated (3,000 rad) splenocytes per ml. TCL were cultured
starting from the third restimulation, in RPMI 1640 with 10%
FCS (GIBCO BRL) and 10% supernatant from rat splenocytes
activated overnight by 2 
 
m
 
g/ml of Con A added every other re-
stimulation.
 
BR E7 T Cell Clone.
 
Every 7–10 d, 2–5 
 
3
 
 10
 
5
 
 T cells per ml
were restimulated with 2–5 
 
3
 
 10
 
6
 
 irradiated (3,000 rad) B10.BR
splenic APC per ml, 3 
 
m
 
g/ml KLH (Calbiochem Corp., San Di-
ego, CA), and 10% rat Con A supernatant. Culture supernatants
were harvested 24 h later and assayed for cytokines.
 
Induction and Scoring of EAE.
 
3 d after the last restimulation
with 30 
 
m
 
M mMBP Ac1-16, 5 
 
3
 
 10
 
6
 
 irradiated splenic APC, and
IL-2, 2–5 
 
3
 
 10
 
7
 
 T cells were washed three times in serum free
RPMI and injected intravenously in the tail veins of nonirradi-
ated recipient mice 6–9 wk old. Mice were monitored daily, and
EAE severity was measured on the 0–5 scale: 0, no symptoms; 0.5,
straight tail; 1, limp tail; 2, paraparesis; 3, paraplegia; 4, quadriple-
gia; 5, moribund. Mice with scores between 4 and 5 were killed.
 
Induction of Cytokine Responses.
 
At the time of restimulation,
aliquots of 0.25–1 
 
3
 
 10
 
6
 
 T cells were washed and plated in 1 ml
of RPMI 1640, 10% FCS. 30 
 
m
 
m mMBP Ac1-16, 5 
 
3
 
 10
 
6
 
 irra-
diated (3,000 rad) splenocytes, and 10% rat Con A supernatant (if
 
,
 
1 
 
3
 
 10
 
6
 
 T cells were used) were added for 24 h, after which su-
pernatant fluids were removed and assayed for levels of cytokines.
For measuring effects of 2 h supernatants on the levels of IFN-
 
g
 
 and
 
1
 
Abbreviations used in this paper:
 
 EAE, experimental autoimmune encepha-
lomyelitis; LA
 
k
 
, L cell fibroblast expressing A
 
k
 
 class II proteins; MBP, my-
elin basic protein; mMBP, mouse MBP; TCL, T cell line. 
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TNF-
 
a
 
, supernatant fluids were obtained from culture of 1 
 
3
 
 10
 
6
 
B10.A and B10.BR T cells per ml restimulated with 30 
 
m
 
m
mMBP Ac1-16 and 5 
 
3
 
 10
 
6
 
 splenocytes per ml for 2 h. Alterna-
tively, 10
 
7
 
 freshly isolated spleen cells per ml were incubated for 2 h
with 10 
 
m
 
g/ml LPS (
 
Escherichia coli
 
 0127:B8; Difco). The 2 h su-
pernatants from each strain (fresh or stored frozen at 
 
2
 
80
 
8
 
C)
were then used as culture media in which 0.5–1 
 
3
 
 10
 
6
 
 B10.BR
T cells per ml were restimulated with 5 
 
3
 
 10
 
6
 
 irradiated B10.BR
splenocytes per ml and 30 
 
m
 
m mMBP for 24 h. In some experi-
ments, 5 
 
3
 
 10
 
5
 
 T cells per ml were restimulated with 30 mm
mMBP Ac1-16 and 5 3 105 per ml irradiated (10,000 rad) trans-
fected L cell fibroblasts expressing Ak class II proteins (LAk cells)
(see reference 58).
Depletion of Splenic T Cells. Spleen cells were dissociated in
serum-free RPMI 1640, resuspended at 4 3 107 per ml, and incu-
bated for 10 min at 48C with 100 ml/ml (NH4)2SO4-concentrated
anti–Thy-1 mAb (Tib 99; American Type Culture Collection).
After incubation for 30 min at 378C with 1:8 diluted Low-Tox
Baby Rabbit Complement (Cedarlane Labs., Westbury, NY), sur-
viving cells were washed three times in RPMI 1640 with 10% FCS
and analyzed by FACSÒ with anti–CD3 mAb or with isotype-
control hamster IgG (Caltag, Burlingame, CA).
Addition or Depletion of Cytokines. Cytokines were added as
follows: mouse recombinant IL-4 (Boehringer Mannheim Corp.,
Indianapolis, IN) at 100 U/ml, mouse recombinant IL-12 (Phar-
Mingen, San Diego, CA) at 10 U/ml, mouse recombinant IFN-g
(Boehringer Mannheim Corp.) at 100 ng/ml, mouse recombi-
nant TNF-a (Genentech Inc., San Francisco, CA) at 2 ng/ml. To
deplete cytokines from the 2 h culture supernatants, anticytokine
antibodies were added to 1 ml of 2-h supernatants from B10.BR
and B10.A cultures at the following concentrations: anti–IL-4
(11B11) at 10 and 20 mg/ml, anti–IL-10 (Sxc.1) at 20 and 40 mg/ml,
anti–IL-12p40 (C17.8) at 20 mg/ml, anti–IL-13 (goat polyclonal)
at 50 and 75 mg/ml, anti–IFN-g (XMG1.2) at 10 and 20 mg/ml,
anti–TNF-a (TN3.19.12) at 50 and 100 mg/ml; anti–TGFb
(rabbit polyclonal) at 40 and 80 mg/ml. After 30 min incubation
at 48C, 100 ml of protein G–coated agarose beads (Pierce Chemi-
cal Co., Rockford, IL) were added to the supernatants. After in-
cubation for 30 min at room temperature, beads were removed
from supernatants by centrifugation at 3,000 rpm for 3 min, and
supernatants were then used as a media for the restimulation of T
cells.
ELISA. Double-antibody sandwich ELISA assays were used.
Plates were coated overnight with a monoclonal antibody specific
for a particular cytokine, washed, and then incubated with cul-
ture supernatant or a cytokine standard overnight. A second
monoclonal antibody, which was biotin-conjugated and which
recognizes an independent epitope of the same cytokine, was
used for detection. Antibodies were biotinylated with D-biotin-
N-hydroxysuccinimide ester (Sigma Chemical Co., St. Louis,
MO). Biotinylated antibodies on the plate were detected with
Streptavidin-horseradish peroxidase (Pierce, Rockford, IL) plus
o-phenylenediamine (Sigma Chemical Co.). Optical densities
were determined at wavelength 5 490 nm using a plate reader
(Molecular Devices Corp., Sunnyvale, CA). Anti–IL-4 mAb BVD4
or 11B11 was used for coating and BVD6 for detection of IL-4.
Mouse recombinant IL-4 (DNAX Research Institute) was used as
a standard. Anti–IL-10 mAb 2A5 (coating) and Sxc.1 (detection)
were used for IL-10. Mouse recombinant IL-10 (DNAX Re-
search Institute) was used as a standard. Anti–IL-12p40 mAb C17.8
(coating) and C15.6 (detection) were used to determine the IL-12
levels. Recombinant murine IL-12, (provided by S. Wolf, Genet-
ics Institute, Cambridge, MA), was used as a standard. Anti-IFN-g
mAb HB170 (coating) and XMG1.2 (detection) were used for
the IFN-g ELISA. Recombinant murine IFN-g (Genentech, Inc.)
was used as a standard.
IL-2 Bioassay. 50 ml of supernatants from TCL restimulated
with serial dilutions of mMBP Ac1-16 and irradiated splenic APC
for 24 h were added to 1 3 104 HT-2 cells per well in 96-well
plates in a final volume of 200 ml. IL-4 was neutralized with
11B11 anti–IL-4 mAb. Murine recombinant IL-2 (Sigma Chemi-
cal Co.) was used as a standard. 16–18 h later [3H]thymidine (1 mCi
per well in 20 ml) was added to plates. After 6–7 h, incubation
plates were harvested (PHD Cell Harvester; Cambridge Technol-
ogy, Inc., Cambridge, MA), and incorporation of [3H]thymidine
was measured by scintillation counting.
TNF Bioassay. The TNF bioassay was carried out as de-
scribed (57). Briefly, 2 3 104 L929 cells per well were plated in
96-well plates and incubated overnight. Serial dilutions of super-
natants from TCL and 1 mg/ml actinomycin C1 (Boehringer Mann-
heim Corp.) were added to wells in a final volume of 200 ml. A
standard curve was prepared using recombinant murine TNF-a
(Genentech, Inc.). After 24 h incubation, 10 ml of 5 mg/ml 3-[4,
5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT;
Sigma Chemical Co.) was added to each well. 4 h later, 100 ml of
solubilization solution containing 50% dimethylformamide and
20% SDS (Sigma Chemical Co.) were added to each well for 1 h,
and the optical densities were determined using a plate reader
(wavelength 5 570 nm; Molecular Devices Corp., Sunnyvale, CA).
Results
T Cells from B10.BR Mice Are Significantly More Encepha-
litogenic in Adoptive Transfer of EAE than B10.A-derived T
Cells. Initial comparison of susceptibility of strains B10.A
and B10.BR to EAE induced in vivo by immunization
with MBP NH2-terminal peptides were uninformative, as
both strains demonstrated comparably low susceptibility to
EAE (average score 5 0.5, data not shown). Freshly iso-
lated B10.A and B10.BR lymph node cells gave very low
proliferative responses to MBP compared to those from Au
strain B10.PL, which is susceptible to EAE (46). The dif-
ferences in susceptibility to EAE and in proliferation of Au-
versus Ak-restricted MBP-primed lymph node cells most
likely reflects higher affinity binding of MBP NH2-terminal
peptides by Au compared to Ak class II proteins (58).
For adoptive transfer of EAE, TCL specific for mMBP
Ac1-16 were generated from B10.PL, B10.A, B10.BR,
and (B10.A 3 B10.BR) F1 animals using splenic APC in
the serial restimulations. After several in vitro restimula-
tions T cells were transferred into nonirradiated recipients
using the EAE adoptive transfer model (59). In two adop-
tive transfer experiments, two independently derived sets of
TCL specific for mMBP Ac1-16 (TCL 1 and TCL 2) were
generated from B10.PL, B10.A, B10.BR, and (B10.A 3
B10.BR) F1 animals. Strain B10.PL was used as a positive
control for the encephalitogenicity of MBP-specific TCL.
The first set of TCL (TCL 1) was restimulated nine times
in vitro and the second set of TCL (TCL 2) was restimu-
lated five times in vitro before transfer into syngeneic re-
cipients. TCL from B10.A and B10.BR strains were also
transferred into (B10.A 3 B10.BR) F1 animals. The sever-
ity of EAE was scored on a standard scale from 0 to 5.442 Novel Genetic Regulation of Cytokine Production
The results of these adoptive transfer experiments are
presented in Table 1. The positive control B10.PL TCL
induced severe EAE. Both TCL from B10.BR mice were
also highly encephalitogenic in syngeneic recipients and
caused disease in F1 recipients. In contrast, both B10.A-
derived TCL failed to induce significant disease in either
B10.A or F1 recipients. F1 T cells transferred into F1 mice
induced weak EAE, though marginally more severe disease
than that induced by B10.A T cells. These results show that
B10.A and B10.BR strains display a significant phenotypic
difference in that TCL from B10.BR induce severe EAE,
whereas TCL from B10.A fail to do so. Low encephalito-
genicity appears to be dominant in the (B10.A 3 B10.BR)
F1 TCL specific for MBP.
We noted that the two B10.BR TCL differed in the se-
verity of EAE induced in F1 recipients. B10.BR TCL 1,
which had been re-stimulated with a random mixture of
B10.BR and B10.A splenocytes, induced less severe EAE
in (B10.A 3 B10.BR) F1 mice than did B10.BR TCL 2,
which had been restimulated with B10.BR APC only. This
suggested that the genetic origin of the APC influenced the
encephalitogenicity of TCL. To test this hypothesis, addi-
tional TCL (TCL 3) were generated, in which lymph node
T cells from B10.A and B10.BR mice were restimulated as
separate lines with B10.A, B10.BR, or (B10.A 3 B10.BR)
F1 splenic APC. After nine restimulations with mMBP
Ac1-16 presented by splenic APC of syngeneic or semi-
syngeneic F1 genetic origin, the TCL were adoptively
transferred into recipients. (TCL restimulated with the re-
ciprocal parental APC did not expand sufficiently in num-
ber to transfer.) As shown in Table 2, neither B10.A TCL
caused significant EAE, consistent with the results with
TCL1 and TCL2. Strikingly, while B10.BR TCL restimu-
lated with B10.BR splenic APC induced severe disease, the
B10.BR TCL restimulated with F1 APC did not cause
EAE. These results indicate that B10.BR splenic APC are
required for the development of encephalitogenicity of
B10.BR TCL and that the non-EAE-promoting pheno-
type of B10.A is dominant in F1 APC.
Cytokine Profiles, but Not Other Parameters Required for En-
cephalitogenicity, Differ among B10.A, B10.BR, and (B10.A 3
B10.BR) F1 TCL. Encephalitogenic B10.BR TCL and
nonencephalitogenic B10.A and F1 TCL were character-
ized for parameters previously shown to be required for the
induction of EAE to determine which parameter is affected
by the genetic differences between these strains. The acti-
vation state of TCL following stimulation with mMBP
Ac1-16 was assayed by examining proliferation, cell surface
levels of Mel-14, LFA-1, VEA (CD69), CD3, and CD4
antigens, and by cell cycle analysis. None of these indices of
activation differed between the B10.A and B10.BR TCL;
all TCL were virtually 100% CD41 and proliferated vigor-
ously in response to MBP Ac1-16 (not shown). The prolif-
erative responses of all TCL were strictly mMBP Ac1-16–spe-
cific and dose-dependent. The TCL restimulated with APC
of syngeneic, F1, or reciprocal parent strain origin dis-
played no allogeneic reactivity. The potential for homing
to the central nervous system was examined by measuring
cell surface levels of a4b1 integrin, VLA-4; no consistent
differences were found between B10.A and B10.BR TCL.
FACSÒ and reverse transcriptase-PCR analysis demon-
strated that the predominant T cell receptor Vb regions ex-
Table 1. MBP-specific TCL from B10.A or (B10.A 3 B10.BR) F1 Mice Are Less Encephalitogenic than MBP-specific
TCL from B10.BR Strain
Clinical signs of EAE
Strain Maximum score Day of onset
Donor TCL* No. Recipient mice Incidence Average (range) Average (range)
B10.PL TCL 1 B10.PL 5/5 1.9 (1–3) 7 (5–10)
B10.BR TCL 1 B10.BR 5/5 2.7 (2–4) 10.6 (7–14)
TCL 2 B10.BR 5/5 3.4 (3–4) 7.2 (6–10)
B10.BR TCL 1 (A 3 BR)F1§ 3/5 1.3 (0.5–2) 13.3 (8–17)
TCL 2 (A 3 BR)F1 5/5 3.8 (3–4) 8.6 (7–10)
B10.A TCL 1 B10.A 4/5‡ 0.75 (0.5–1) 7 (4–12)
TCL 2 B10.A 4/5 0.5 (0.5–1) 8 (7–15)
B10.A TCL 1 (A 3 BR)F1 3/4 0.66 (0.5–1) 9 (6–11)
TCL 2 (A 3 BR)F1 3/5 0.5 16 (12–20)
(A 3 BR)F1 TCL 2 (A 3 BR)F1 4/5 1 (0.5–1.5) 14.2 (9–20)
*TCL 1 cells were re-stimulated nine times in vitro before transfer, using syngeneic APC for B10.PL TCL and a random mixture of B10.A and
B10.BR APC for B10.A and B10.BR TCL. TCL 2 cells were restimulated five times before transfer, using syngeneic splenic APC.
‡One out of five B10.A mice injected with B10.A T cells died shortly after the experiment, likely due to injury or stress.
§(A 3 BR)F1 is an abbreviation of (B10.A 3 B10.BR) F1.443 Conboy et al.
pressed by B10.A and B10.BR TCL were extremely simi-
lar (predominantly Vb 4, 8, and 13), and somewhat more
heterogeneous than that of the B10.PL MBP TCL (50%
Vb 8) (not shown). The levels and sequences of the Ak class
II presenting element for MBP Acl-16 were also examined
for strains B10.A and B10.BR. The levels of Ak expressed
by splenic B cells, splenic macrophages, and peritoneal
macrophages from B10.A and B10.BR mice were found to
be identical by flow cytometry. Splenic cDNA for Aak and
Abk chains were amplified from both strains and sequenced
using direct PCR sequencing and were found to be identi-
cal over the entire protein coding sequence (not shown).
These results indicate that the class II presenting elements,
mMBP Ac1-16–specific TCR repertoire, and indices of
activation are identical between B10.A and B10.BR.
In contrast, comparison of the cytokine profiles of B10.A
and B10.BR TCL revealed differences which correlated
with their encephalitogenicity. Data for the TCL 2 lines are
shown in Fig. 1. The B10.A TCL stimulated with peptide
and B10.A splenic APC displayed the Th2 phenotype, ex-
pressing very low levels of IFN-g, IL-2, and TNF-a and
high levels of IL-4 and IL-10. Levels of Th1-promoting
IL-12 (made by APC) were undetectable. In contrast, the
B10.BR TCL displayed the Th1 phenotype, secreting very
little IL-4 and IL-10, and high levels of IFN-g, IL-2, and
TNF-a. IL-12 levels were also significantly higher. TNF-a
ELISA results (not shown) were nearly identical (within
10%) to the TNF bioassay results, and as TNF biological
activity was totally blocked with the anti–TNF-a mAb
TN3-19.12 (see below), all of the TNF activity detected in
these TCL supernatants appeared to be TNF-a. Superna-
tants from the (B10.A 3 B10.BR) F1 TCL stimulated with
peptide and F1 APC contained intermediate amounts of
the tested cytokines, but the levels were closer to those
from B10.A than B10.BR TCL. Thus, TCL from B10.A
mice produced a Th2, low TNF-a response, T cells from
B10.BR produced a Th1, high TNF-a response, and the
Th2, low TNF-a phenotype was dominant in the (B10.A 3
B10.BR) F1 T cell cultures. These results indicated that ge-
netic difference between B10.A and B10.BR controls a reg-
ulator of Th cytokines.
The Cytokine Profile of the B10.BR TCL Is Influenced by
the Genetic Origin of the APC Used for In Vitro Restimula-
tion. The cytokine profiles of the third set (TCL 3) of
MBP-specific T cell lines serially restimulated with splenic
APC of varying genetic origins were also examined. The
cytokine responses of the six TCL were determined after
the third, fourth, fifth, ninth, and tenth restimulations. We
found that the genetic origin of the splenic APC used for
restimulations greatly influenced the cytokine profile of
Table 2. Encephalitogenicity of B10.BR MBP-specific T Cells Is Reduced by Re-stimulation with (B10.A 3 B10.BR) F1 Splenic APC
Strain
Clinical signs of EAE
Incidence
Maximum score Day of onset
Donor TCL (TCL 3) APC Recipient mice Average (range) Average (range)
B10.BR B10.B B10.BR 5/5 3.8 (3–4) 7.5 (5–10)
B10.BR (A 3 BR)F1 B10.BR 1/4 0.5 9
B10.A B10.A B10.A 4/5 0.5 9 (6–12)
B10.A (A 3 BR)F1 B10.A 3/5 0.5 12.5 (9–16)
Figure 1. Cytokine levels of MBP-specific TCL stimulated overnight with syngeneic APC. Established lymph node TCL (TCL 2) from mMBP Ac1-
16–immunized B10.A, B10.BR, and (B10.A 3 B10.BR) F1 mice were restimulated for the fifth time with mMBP Ac1-16 and irradiated splenic APC.
After 24 h, culture supernatants were harvested. Additional cells harvested 3 d after the same fifth restimulation were used for adoptive transfer experi-
ment EAE (see Table 1). Data presented for TNF are means and standard deviations of two bioassays performed on triplicate wells for each sample (n 5
6). Data presented for IFN-g, IL-12, IL-4, and IL-10 are means and standard deviations of triplicate wells for each sample (n 5 3). Data presented for
IL-2 are means and standard deviations of two IL-2 bioassays performed in duplicate wells for each sample (n 5 4).444 Novel Genetic Regulation of Cytokine Production
the B10.BR TCL. Thus, the Th1, high TNF-a phenotype
of the B10.BR TCL was maintained only by syngeneic
B10.BR splenic APC; very little IFN-g, TNF-a, or IL-2
was produced by the B10.BR TCL serially restimulated
with F1 or B10.A APC (Fig. 2). For IL-4, all three of the
B10.A TCL had higher levels than the B10.BR TCL (Fig.
2 C), and B10.BR T cells maintained on B10.BR APC
produced the lowest IL-4 levels. IL-10, B10.A, and F1
APC, but not B10.BR APC, supported levels similar to
those produced by B10.A TCL (Fig. 2 D). A Th2, low
TNF-a profile was seen for all B10.A TCL irrespective of
the source of APC.
Expression of the Th1, high TNF-a phenotype only by
B10.BR TCL serially restimulated with B10.BR APC cor-
relates well with the encephalitogenicity of this TCL in
adoptive transfer of EAE (Table 2). These results indicate
that B10.A and F1 APC prevent the development of the
Th1, high TNF-a encephalitogenic cytokine phenotype in
response to MBP.
IFN-g and TNF-a Production by Established Th1 B10.BR
TCL can Be Downregulated by a Single Restimulation with
B10.A APC or in the Presence of 2-h Supernatants from Acti-
vated B10.A Cultures.  To determine whether a single re-
stimulation with B10.A APC can alter the production of
IFN-g and TNF-a by established B10.BR-derived Th1s,
two independently derived Th1 MBP-specific B10.BR TCL
Figure 2. Cytokines produced by TCL (TCL 3) from B10.A and
B10.BR mice are influenced by the source of APC (B10.A, B10.BR, or
F1) used for in vitro restimulations. (A–D) After the third, fourth, fifth,
ninth, and tenth restimulations of TCL with mMBP Ac1-16 and irradi-
ated splenic APC of the indicated origin, T cells were restimulated for 24 h
with peptide and APC of the same origin. Adoptive transfer of EAE was
performed after the ninth restimulation (see Table 2). Supernatant fluids
were analyzed for cytokines. In Fig. 2 D, the points for the B10.BR
TCL-3–B10.A APC are 37 ng/ml of IL-10 after the ninth restimulation
and 45 ng/ml of IL-10 after the tenth restimulation. Data presented are
average of duplicate wells for each sample. (E) At the ninth restimulation,
TCL 3 described for A–D were restimulated for 24 h with peptide and
APC of the same (indicated) origin. Supernatant fluids depleted of IL-4
were analyzed for IL-2 levels, using the growth factor dependent cell line
HT-2. Data presented are means and standard deviations of four wells for
each sample (n 5 4).
Figure 3. Downregulation of B10.BR TCL IFN-g and TNF-a pro-
duction by B10.A APC or by 2-h supernatant from activated B10.A
APC. (A–C) Independent experiments with MBP-specific B10.BR TCL
3 (A and B) and TCL 4. TCL were restimulated for 24 h in the presence
of B10.BR or B10.A splenic APC, or splenic APC depleted of T cells (A,
lower bars). In some cultures, B10.BR TCL were restimulated with
B10.BR APC and MBP peptide in the presence of 2-h supernatant fluids
from cultures of B10.BR or B10.A TCL stimulated with syngeneic APC
and MBP peptide (B, bottom bars; C, middle bars), or in the presence of 2-h
supernatants from B10.BR or B10.A spleen cells stimulated with LPS (C,
bottom bars). Data presented are means and standard deviations of triplicate
wells for each sample (n 5 3). All experiments were repeated at least three
times with similar results.445 Conboy et al.
(TCL 3 and TCL 4, both of which had been maintained
with syngeneic B10.BR APC) were restimulated overnight
with B10.BR or B10.A APC before harvesting superna-
tants for cytokine assays. As shown in Fig. 3, A–C (top bars),
IFN-g and TNF-a levels were downregulated by 40–60%
when B10.A, instead of B10.BR, APC were used for the
single restimulation. Similar downregulation of IFN-g
and TNF-a was observed when B10.A (but not B10.BR)
T cell–depleted splenic APC were used to restimulate
B10.BR TCL (Fig. 3 A, bottom bars). Irrespective of the ge-
netic source of APC, IL-2 levels and proliferative responses
remained high and IL-4 was not induced (not shown).
To determine whether the inhibitory activity of B10.A
APC on IFN-g and TNF-a levels was mediated by a solu-
ble factor, the two B10.BR TCL were restimulated with
mMBP Ac1-16 and B10.BR splenic APC in the presence
of supernatant fluids from a culture of B10.A TCL stimu-
lated with B10.A splenic APC and mMBP Ac1-16 for 2 h.
The 2-h time point was chosen because most cytokines in-
duced by activation of T cells and APC are not detectable
at this time point, except TNF-a and -b (60, 61; and our
unpublished data). The B10.A culture-derived 2-h super-
natant downregulated IFN-g and TNF-a production by at
least 50% relative to control cultures with 2-h supernatants
from B10.BR T cells and APC plus peptide (Fig. 3 B, bot-
tom bars, and C, middle bars), comparable to the effects of
B10.A APC themselves. Similar results were obtained with
B10.BR TCL 4 stimulated with B10.BR splenic APC and
MBP peptide in the presence of supernatants from freshly-
isolated B10.A and B10.BR spleen cells activated for 2 h
with LPS (Fig. 3 C, bottom bars). Thus, downregulation of
IFN-g and TNF-a production seems to be mediated by a
soluble factor secreted by B10.A splenic APC within the
first 2 h after activation by antigen-stimulated T cells or by
LPS. However, a single restimulation of B10.BR TCL with
B10.A splenic APC or in the presence of 2-h supernatant
from B10.A cultures did not induce any IL-4 expression in
B10.BR T cells (see below). B10.A TCL remained Th2,
low TNF-a producing cells irrespective of the genetic source
of APC or 2 h supernatant (not shown and see below).
The B10.A-derived Soluble Cytokine Regulatory Factor
Functions when Ak-expressing L Cell Fibroblasts Are Used as
APC. To begin to clarify the target of action of the
B10.A-derived regulatory factor, B10.BR or B10.A T cells
(TCL 4) were restimulated twice with mMBP Ac1-16 pre-
sented by nonprofessional APC (Ak-expressing L cells
which do not produce splenic APC-derived cytokines), in
the presence of 2-h supernatant from B10.A cultures. In ei-
ther normal medium or in the 2-h B10.BR supernatant,
B10.BR T cells produced high levels of IFN-g and TNF-a,
and B10.A T cells produced high levels of IL-4 with little or
no TNF-a and IFN-g. However, the levels of IFN-g and
TNF-a produced by B10.BR TCL were reduced in the
presence of 2-h supernatant from B10.A cultures, similar to
the effects seen when professional splenic APC were used
(Fig. 4). This result indicates that B10.A-derived factor
does not require the presence of splenic APC for its action
and probably acts directly on the responding T cells.
The B10.A-derived Factor Acts Independently of Known
Th1/Th2 Regulatory Cytokines in Downregulating B10.BR
Production of IFN-g and TNF-a.  To assess whether down-
regulation of IFN-g and TNF-a by B10.A APC is medi-
ated by or depends on any of the known Th1/Th2 regula-
tors, 2-h culture supernatants derived from B10.BR or B10.A
TCL/APC cultures were depleted of IL-4, IL-10, IL-12p40,
IL-13, TNF-a, IFN-g, and TGF-b and tested for their ef-
fects on IFN-g and TNF-a production by B10.BR TCL 4
restimulated with B10.BR APC and mMBP peptide. Cyto-
kine depletion did not diminish the downregulatory activ-
ity of the B10.A culture supernatant (Fig. 5, A and B). Se-
rial dilutions of B10.A and B10.BR 2-h culture supernatants
(Fig. 5 C) demonstrated that the downregulatory activity of
Figure 4. Supernatant from
B10.A T cells activated with
B10.A APC for 2 h downregu-
lates IFN-g and TNF-a produc-
tion by B10.BR Th1 cells when
Ak-expressing L cell fibroblasts
are used as APC. B10.BR (top
bars) or B10.A (bottom bars) TCL
4 were activated with mMBP
Ac1-16 and Ak-expressing L cell
fibroblasts as APC for two con-
secutive restimulations in either
normal medium or in 2-h super-
natants from B10.BR or B10.A
T cells activated with syngeneic
splenic APC. Culture superna-
tants were harvested 24 h after
restimulation and IFN-g, TNF-a,
and IL-4 were measured as
above. Data presented are means
and standard deviations of tripli-
cate wells for each sample (n 5
3). Similar results were obtained
in two additional experiments.446 Novel Genetic Regulation of Cytokine Production
B10.A-derived factor is rapidly lost by dilution, indicating
that any depletion of the downregulatory cytokine would
have been detected. Essentially identical results were ob-
tained when the anti-cytokine antibodies were also used at
half the concentrations (not shown).
As summarized in Fig. 6, blocking or adding IL-4 and
IL-12 (alone or in combinations) did not reduce the down-
regulatory effects of B10.A APC on TNF-a levels, al-
though there were effects on the absolute levels of TNF-a
production. In contrast, adding IFN-g significantly re-
duced the downregulation by B10.A APC. For IFN-g pro-
duction, adding TNF-a did not prevent the downregula-
tion of IFN-g by B10.A APC, and adding IL-4 did not
synergize with this downregulation (Fig. 6 B). As expected
because of their pro-Th1 effects, addition of IL-12 alone,
or in combination with anti-IL-4, did increase the overall
IFN-g levels and reduced the downregulation of IFN-g by
B10.A APC.
In the experiments shown in Figs. 5 and 6, none of the
cytokines or anti-cytokine antibodies induced detectable
levels of IL-4 production by the B10.BR TCL (not shown).
Overall the results shown in Figs. 5 and 6 suggest that the
B10.A-derived factor acts independently of known cyto-
kine regulators, and that strong pro-Th1 conditions can over-
come its downregulatory effect on TNF-a and IFN-g.
B10.A APC Downregulate IFN-g and TNF-a Production
by a Th1 Clone with Different Antigen and MHC Restriction
Specificities. The cytokines produced by the B10.BR-
derived, KLH-specific, Ek-restricted Th1 clone BR E7 (62)
were assayed after two consecutive restimulations with
B10.BR or B10.A splenic APC. As shown in Fig. 7, pre-
Figure 5. Downregulation of IFN-g and TNF-a levels is not affected
when 2-h B10.A culture supernatant is depleted of known Th1/Th2 cy-
tokine regulators. (A and B) B10.BR or B10.A T cells (TCL 4) were re-
stimulated with mMBP Ac1-16 and syngeneic splenic APC for 2 h. Neu-
tralizing antibodies specific for mouse IL-4, IL-10, TNF-a, IFN-g, TGF-b,
IL-13, and IL-12p40 were added to these culture supernatants for 30 min,
and antibody–cytokine complexes were removed using protein G–coated
agarose beads. Cytokine depleted 2-h supernatants were then used as me-
dia in which B10.BR TCL 4 were restimulated with mMBP Ac1-16 and
B10.BR splenic APC for 24 h. IFN-g (A) and TNF-a (B) levels were
measured as above. Lower levels of TNF-a after treatment with anti–
TNF-a antibody and protein G beads were due to the presence of resid-
ual anti–TNF-a antibody, which has low affinity for protein G in me-
dium with serum. Neutralizing antibodies were used at concentrations
equal to (not shown) and twice what were recommended by the manu-
facturers for complete neutralization of cytokine levels produced by high
expressing cells, giving similar results. Data presented are means and stan-
dard deviations of triplicate wells for each sample (n 5 3). (C) B10.BR
TCL 4 cells were restimulated with B10.BR splenic APC and mMBP
Ac1-16 in 2-h culture supernatants from B10.A or B10.BR TCL 4, used
either undiluted or at serial 1:2 dilutions in RPMI, 10% FCS. TNF-a
levels are means and standard deviations of triplicate wells for each sample
(n 5 3).
Figure 6. Modulation of downregulatory activity by addition or neu-
tralization of known cytokine regulators during restimulation of B10.BR
T cells with either B10.BR or B10.A splenic APC. B10.BR T cells (TCL 4)
were restimulated with mMBP Ac1-16 and either B10.BR or B10.A
splenic APC for 24 h in the absence or presence of mouse recombinant
IL-4, IFN-g, TNF-a, and IL-12 alone or combination with neutralizing
antibody specific for mouse IL-12, or mouse IL-4. Cytokine levels result-
ing from each treatment are expressed as a percentage of control (B10.BR
TCL, B10.BR APC, and peptide with no cytokine or antibody addi-
tions). Data presented are means and standard deviations of triplicate wells
for each sample (n 5 3). At least two independent experiments were per-
formed for each treatment, yielding similar results.447 Conboy et al.
sentation of KLH by B10.A APC results in the progressive
reduction of IFN-g and TNF-a levels produced by this
Th1 clone. Thus, the B10.A APC-derived factor acts inde-
pendently of the specificity of the Th1 and is able to down-
regulate IFN-g and TNF-a production by a fully commit-
ted clonal Th1 population.
Discussion
This paper presents evidence for a genetic difference(s)
between inbred strains B10.A and B10.BR that act(s) in
APC to control Th1/Th2 cytokine profiles and the en-
cephalogenicity of MBP-Ac1-16–specific T cells. The reg-
ulatory effects are manifested both at the time of commit-
ment to Th1/Th2 phenotypes as B10.A APC block the
development of IL-2, IFN-g, and TNF-a production, and
in the production of IFN-g and TNF-a by committed
Th1s as a single restimulation with B10.A-derived APC or
in the presence of B10.A-derived supernatant downregu-
lates the production of these cytokines by established Th1
B10.BR cells. The downregulation of IFN-g and TNF-a
production by a B10.BR-derived, KLH-specific, Ek-restricted
T cell clone when restimulated by KLH presented by B10.A
APC demonstrates that the regulatory effects of B10.A-
derived factor (a) are not limited to responses of MBP-spe-
cific, Ak-restricted Th1s, and (b) can act by affecting indi-
vidual clonal populations of mature Th1s rather than by
expanding uncommitted precursors or Th0 cells. The in-
duction of comparable proliferative and IL-2 responses in
Th1 B10.BR TCL by MBP peptides presented by either
B10.A or B10.BR APC indicates that B10.A APC do not
inhibit the activation of these T cells, but downregulate pro-
duction of IFN-g and TNF-a. The target of the factor ap-
pears to be the responding T cells, as the downregulatory
effects of the B10.A supernatants are observed when MBP
peptide is presented to B10.BR T cells by nonprofessional
APC, Ak-expressing L cell fibroblasts. B10.A TCL maintain
a Th2, low TNF-a cytokine profile irrespective of the ge-
netic source of the APC or 2-h supernatant, suggesting that
they had become committed in vivo, perhaps due to the
pro-Th2 effects of their own APC. The Th2-inducing
phenotype of B10.A is dominant in (B10.A 3 B10.BR) F1
cells.
The identity of the APC cell type(s) within the irradiated
B10.A splenocyte population that is responsible for the
downregulation of IFN-g and TNF-a production has not
yet been determined. Splenic T cells do not seem to be re-
quired for the downregulation. Preliminary results indicate
that B10.A-derived splenic macrophages have downregula-
tory activity, while splenic B cells do not (not shown).
While the results to date indicate that the downregulation
of IFN-g and TNF-a production by B10.BR Th1s is me-
diated by B10.A APC, we have not ruled out the possibil-
ity that activated B10.A T cells may also produce the
downregulatory factor.
The B10.A-derived soluble factor that modulates Th cy-
tokine production appears to be novel. The results of add-
ing or blocking cytokines implicated in regulating Th1/
Th2 cytokine production indicate that the downregulatory
effects of this factor probably do not act through or require
IL-4, IL-10, IL-13, IL-12p40, TGF-b, IFN-g, or TNF-a.
The B10.A-derived factor also acts independently of pros-
taglandin E2, an APC-derived molecule known to inhibit
production of IFN-g by activated CD41 T cells (63, 64),
indicated by the failure of indomethacin to block downreg-
ulation of IFN-g and TNF-a production by B10.A APC
(not shown). The activity of this factor in downregulating
IFN-g production also differs from that of IL-4 in that IL-4,
but not the factor, blocks IFN-g induction by IL-12
through its inhibition of signaling through the IL-12 recep-
tor (21).
The finding that the downregulatory effects of the B10.A-
derived factor on Th1 IFN-g production is overcome by
exogenous IFN-g and by IL-12, especially in combination
with anti–IL-4, suggests that the in vivo effects of the
B10.A-derived factor should be most evident in the ab-
sence of strong pro-Th1 conditions. This may occur during
initial antigen priming, especially when T cell responses are
weak, e.g., with poor antigens such as the MBP Ac1-16
peptide, and perhaps more generally with self antigens. The
apparent direct effect of B10.A APC and of the secreted
cytokine regulatory factor on IFN-g production by mature
Th1s, even when IL-4 has been depleted, suggests that in-
hibition of IFN-g production may be the primary mecha-
nism by which the B10.A-derived factor skews initial Th1/
Th2 subset determination. When T cells are strongly acti-
vated, or where significant levels of IL-12 and/or IFN-g are
already present, the B10.A-derived factor may not down-
regulate IFN-g production.
This may help to explain why the factor’s anti-Th1 reg-
ulatory effects in B10.A mice may not have been observed
in earlier studies of Leishmania susceptibility in inbred
strains, which showed B10.A to be resistant (44), or in in
Figure 7. Downregulatory effects of B10.A splenic APC on IFN-g and
TNF-a production by a B10.BR-derived, KLH-specific, Ek-restricted T
cell clone. The BR E7 T cell clone was activated with KLH and either
B10.BR or B10.A splenic APC for two consecutive restimulations. Cul-
ture supernatants were harvested and assayed for TNF-a (A) and IFN-g
(B) 24 h after stimulation. Data presented are means and standard devia-
tions of triplicate wells for each sample (n 5 3). Similar results were
ovserved in at least two additional experiments.448 Novel Genetic Regulation of Cytokine Production
vitro studies of Th1/Th2 commitment of T cells from
B10.A TCR transgenic mice (19). Unlike IFN-g, down-
regulation of TNF-a is maintained in the presence of ex-
ogenous IL-12, implying IFN-g and TNF-a are regulated
independently.
The basis for the difference between B10.A and B10.BR
APC in downregulatory factor production remains to be
determined. The gene for the factor itself could be poly-
morphic, resulting in differences in the levels or activity of
the factor produced. Alternatively, the polymorphism could
be in gene(s) that indirectly affect factor activity by control-
ling its synthesis, modification, or secretion. Initial analysis
of the genetics downregulatory activity have yielded sur-
prising results. We anticipated that the gene would be H-2-
linked, as B10.A and B10.BR are H-2 congenic strains on
the C57BL/10 background; the H-2k haplotype of B10.BR
was derived from C57BR and the H-2a recombinant haplo-
type of B10.A (k haplotype in the H-2K-Ea region, d hap-
lotype telomeric to Ea) was derived from strain A/WySn
(65, 66). However, preliminary tests of (B10.A 3 B10.BR)
F2 progeny and (F1 3 B10.BR) backcross progeny, in
which their splenic APC were assayed for the ability to
downregulate TNF-a production by MBP-specific B10.BR
TCL, suggest that the polymorphic gene(s) controlling fac-
tor production is (are) not linked to H-2. If confirmed, this
would indicate that strains B10.A and B10.BR also differ
by a non-H-2 locus or loci. Splenic APC from A strain
subline A/WySn and from the A strain background H-2
congenic A.TL downregulate IFN-g and TNF-a produc-
tion by B10.BR TCL in response to MBP Ac1-16. Thus,
the production of the downregulatory factor by B10.A appears
to be due to a contaminating non-H-2 gene(s) derived from
the A/WySn donor of the H-2a haplotype, despite the 10
backcrosses to the C57BL/10 inbred partner during the
initial derivation of B10.A (65).
The genetic and phenotypic properties of the B10.A-
derived factor clearly distinguish it from the other major
polymorphic gene previously shown to regulate Th1/Th2
cytokine production. Described initially in the Leishmania
system, this polymorphic gene regulates resistance (associ-
ated with Th1 responses) to L. major (reviewed in 47), and
more recently has been shown to regulate cytokine re-
sponses to other antigens (44, 49, 67). The Leishmania resis-
tance gene acts in T cells to regulate their Th1/Th2 cyto-
kine phenotypes (67, 47), whereas the results reported here
show that the B10.A-derived factor acts in the APC used
for T cell activation. Also, for Leishmania, most inbred
strains, including B10.A and A strains, have the resistant
(Th1) phenotype (44). Finally, in the Leishmania system,
the resistant (Th1) phenotype is largely dominant in het-
erozygotes (47, 68), whereas for the B10.A-derived factor
discussed here, the Th2-promoting phenotype is dominant
or co-dominant in (B10.A 3 B10.BR) F1 mice.
While the effects of the B10.A-derived factor have been
characterized in only a few mouse strains, this gene may
represent a previously identified or a new member of a
growing number of polymorphic genes known to influ-
ence susceptibility to autoimmune diseases (48). Additional
studies are underway to characterize more fully the genetics
and mechanisms of action of this novel cytokine regulatory
gene. Identification of the soluble cytokine regulatory fac-
tor controlled by the B10.A-derived gene, its cellular ori-
gin, and its mode of action, should contribute to decipher-
ing the mechanisms regulating Th1s and Th2s and their
pathogenicity in autoimmune, inflammatory, and allergic
disorders.
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